Amgen/NNP Inc./NNP said/VBD its/PRP$ second-quarter/JJ earnings/NNS increased/VBD more/RBR than/IN tenfold/RB to/TO $/$ 3.9/CD million/CD ,/, or/CC 22/CD cents/NNS  a/DT share/NN ,/, due/JJ to/TO increased/VBN sales/NNS of/IN the/DT company/NN 's/POS new/JJ antianemia/JJ drug/NN for/IN kidney/NN patients/NNS ./.
The/DT Thousand/NNP Oaks/NNP ,/, Calif.-based/JJ biotechnology/NN company/NN reported/VBD a/DT 97/CD %/NN increase/NN in/IN revenue/NN to/TO $/$ 42.5/CD million/CD for/IN the/DT quarter/NN ended/VBN Sept./NNP 30/CD ./.
the/DT year-ago/JJ period/NN ,/, Amgen/NNP reported/VBD net/JJ income/NN of/IN $/$ 320,000/CD ,/, or/CC two/CD cents/NNS  a/DT share/NN ,/, on/IN revenue/NN of/IN $/$ 21.5/CD million/CD ./.
the/DT six/CD months/NNS ,/, the/DT company/NN reported/VBD a/DT more/JJR than/IN sixfold/JJ increase/NN in/IN earnings/NNS to/TO $/$ 4.7/CD million/CD ,/, or/CC 26/CD cents/NNS  a/DT share/NN ,/, from/IN $/$ 625,000/CD ,/, or/CC four/CD cents/NNS  a/DT share/NN  a/DT year/NN ago/RB ./.
Revenue/NN rose/VBD 77/CD %/NN to/TO $/$ 72.6/CD million/CD ,/, from/IN last/JJ year/NN 's/POS $/$ 41/CD million/CD ./.
